590 related articles for article (PubMed ID: 29496294)
21. Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer.
Olmez F; Oglak SC; Akgol S; Olmez OF; Bilici A; Akbayir O; Ozkose ZG; Can E; Unal O; Sirinoglu HA
J Coll Physicians Surg Pak; 2023 Jun; 33(6):666-672. PubMed ID: 37300263
[TBL] [Abstract][Full Text] [Related]
22. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.
Lee KS; Kwak Y; Ahn S; Shin E; Oh HK; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
Cancer Immunol Immunother; 2017 Jul; 66(7):927-939. PubMed ID: 28405764
[TBL] [Abstract][Full Text] [Related]
24. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
25. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
26. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
Asaka S; Yen TT; Wang TL; Shih IM; Gaillard S
Mod Pathol; 2019 Apr; 32(4):576-584. PubMed ID: 30401949
[TBL] [Abstract][Full Text] [Related]
27. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
28. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
29. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
30. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
[TBL] [Abstract][Full Text] [Related]
31. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
32. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
33. Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
Stelloo E; Jansen AML; Osse EM; Nout RA; Creutzberg CL; Ruano D; Church DN; Morreau H; Smit VTHBM; van Wezel T; Bosse T
Ann Oncol; 2017 Jan; 28(1):96-102. PubMed ID: 27742654
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
36. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
Goeppert B; Roessler S; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Pfeiffenberger J; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
Br J Cancer; 2019 Jan; 120(1):109-114. PubMed ID: 30377340
[TBL] [Abstract][Full Text] [Related]
37. Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic pms2 germline mutations.
Leenen CH; Geurts-Giele WR; Dubbink HJ; Reddingius R; van den Ouweland AM; Tops CM; van de Klift HM; Kuipers EJ; van Leerdam ME; Dinjens WN; Wagner A
Clin Genet; 2011 Dec; 80(6):558-65. PubMed ID: 21204794
[TBL] [Abstract][Full Text] [Related]
38. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
Liu S; Gӧnen M; Stadler ZK; Weiser MR; Hechtman JF; Vakiani E; Wang T; Vyas M; Joneja U; Al-Bayati M; Segal NH; Smith JJ; King S; Guercio S; Ntiamoah P; Markowitz AJ; Zhang L; Cercek A; Garcia-Aguilar J; Saltz LB; Diaz LA; Klimstra DS; Shia J
Mod Pathol; 2019 Jan; 32(1):110-121. PubMed ID: 30166615
[TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
40. Novel Biocartis Idylla™ cartridge-based assay for detection of microsatellite instability in colorectal cancer tissues.
Mindiola-RomeroMD AE; GreenBS DC; Al-TurkmaniPhD MR; GodwinBS KN; MackayBS AC; TafeMD LJ; RenMD B; TsongalisPhD GJ
Exp Mol Pathol; 2020 Oct; 116():104519. PubMed ID: 32822722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]